Huntington’s disease (HD) is an autosomal dominant, inherited, neuropsychiatric
disease that gives rise to progressive motor, cognitive and
behavioural symptoms. Current drug therapy has no effect on the
progression of disability, and the need for any pharmacological treatment
should be carefully considered. Hyperkinesias and psychiatric symptoms may
respond well to pharmacotherapy, but neuropsychological deficits and
dementia remain untreatable. Pharmacological intervention in the treatment
of the movement disorder of HD is aimed at restoring the balance of neurotransmitters
in the basal ganglia. A surprising amount of current drug
therapy of HD in clinical practice is based on studies published before 1990.
The authors conducted a systematic review of pharmacological therapy in HD
using the available papers that were published between 1990 and 2006.
http://www.huntingtonsociety.ca/english/uploads/80_HD_therapy_EOP.pdf
disease that gives rise to progressive motor, cognitive and
behavioural symptoms. Current drug therapy has no effect on the
progression of disability, and the need for any pharmacological treatment
should be carefully considered. Hyperkinesias and psychiatric symptoms may
respond well to pharmacotherapy, but neuropsychological deficits and
dementia remain untreatable. Pharmacological intervention in the treatment
of the movement disorder of HD is aimed at restoring the balance of neurotransmitters
in the basal ganglia. A surprising amount of current drug
therapy of HD in clinical practice is based on studies published before 1990.
The authors conducted a systematic review of pharmacological therapy in HD
using the available papers that were published between 1990 and 2006.
http://www.huntingtonsociety.ca/english/uploads/80_HD_therapy_EOP.pdf
0 comments:
Post a Comment